Roles of convergent RNA polymerase II transcription to HIV-1 latency and reactivation
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
PROJECT SUMMARY Although HIV-1 infection can be controlled through long-term treatment with anti-retroviral therapy (ART), a true cure has been intangible. Reservoir cells endure over time and support latent HIV-1 reactivation upon therapy cessation, yet little is known about the underlying molecular mechanisms. Our lab has recently identified previously unprecedented mechanistic details in the process of RNA polymerase (Pol II) transcription, which might have implications for the regulation of latency maintenance and reactivation in reservoir cells. Specifically, we found a form of convergent Pol II (antisense and downstream of the 5’-LTR) that we will explore in this research proposal to help fill this knowledge gap, and provide key insights into HIV-1 biology as well as cure strategies. The major goal of this grant application is to define the role(s) of the convergent Pol II form to the process of sense HIV-1 transcription from the 5’-LTR during latency and reactivation. We will accomplish this goal by leveraging genetic assays for HIV-1 proviral genome engineering and high-resolution genomic assays in immortalized cell models of latency with cross-validation in primary cell models to bolster physiologic relevance. We will explore the central hypothesis that the convergent Pol II form is required to maintain proper dynamics of sense HIV-1 transcription to facilitate the latency-reactivation switch. We will test if the convergent Pol II form influences HIV-1 transcription in the various phases of the multi-phase HIV-1 transcription program (basal, host and viral) with and without Tat function. We propose to build on our recent findings to gain a deeper understanding of how convergent Pol II controls HIV-1 transcription for latency reactivation in the host and viral phases of the HIV-1 transcriptional program. These goals are reflected in two Specific Aims: assess the function of convergent Pol II pausing to HIV-1 transcription latency and reactivation (Aim 1), and cross validate the presence of convergent Pol II in a primary cell model of latency (Aim 2). If successful, this project will yield a better understanding of the underlying molecular mechanisms by which sense and convergent Pol II forms operate (jointly or independently) to promote HIV-1 transcription during latency reactivation, collectively having a sustained impact in the field. In keeping with NIAID’s mission of ending the HIV-1 epidemic, our long-term objective is to leverage these basic discoveries to help devise novel and alternative cure strategies. We envision that the fundamental knowledge gained by this research could be used in future studies beyond the scope (e.g., by exploiting the convergent Pol II form) to permanently silence transcription to achieve the long-awaited HIV-1 remission.
Grant Summary
Roles of convergent RNA polymerase II transcription to HIV-1 latency and reactivation is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $249K for university, nonprofit, healthcare org. Applications are due 2028-06-30 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $249K
2028-06-30
- 1Confirm your organization is eligible for Roles of convergent RNA polymerase II transcription to HIV-1 latency and reactivation from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Roles of convergent RNA polymerase II transcription to HIV-1 latency and reactivation: Frequently Asked Questions
Who is eligible for the Roles of convergent RNA polymerase II transcription to HIV-1 latency and reactivation?
Roles of convergent RNA polymerase II transcription to HIV-1 latency and reactivation is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Roles of convergent RNA polymerase II transcription to HIV-1 latency and reactivation provide?
Roles of convergent RNA polymerase II transcription to HIV-1 latency and reactivation provides up to $249K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Roles of convergent RNA polymerase II transcription to HIV-1 latency and reactivation deadline?
Applications for Roles of convergent RNA polymerase II transcription to HIV-1 latency and reactivation are due 2028-06-30 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Roles of convergent RNA polymerase II transcription to HIV-1 latency and reactivation?
To apply for Roles of convergent RNA polymerase II transcription to HIV-1 latency and reactivation, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.